the aid library

LIST OPTIONS

Filter

10516

Report of a global meeting on yaws eradication surveillance, monitoring and evaluation: Geneva, 29–30 January 2018

World Health Organization WHO; Institutional research information sharing iris (2018) C_WHO

Report of a global meeting on yaws eradication surveillance, monitoring and evaluation: Geneva, 29–30 January 2018. World Health Organization.

Download (137)

View PDF (191)

Global elimination of dog-mediated human rabies. Report

World Health Organization (WHO) (2016) C_WHO

Rabies remains an under-reported neglected zoonosis with a case-fatality rate of almost 100% in humans and animals. Dog-mediated human rabies causes tens of thousands of human deaths annually despite being 100% preventable. More than 95% of human cases are caused by the bite of a rabies-infected dog... more

Download (134)

View PDF (169)

Inclusión de las personas mayores en la planificación para emergencias: Perspectivas durante y después de la pandemia de COVID-19

World Health Organisation (WHO) (2023) C_WHO

En la Región de las Américas, las poblaciones están envejeciendo y se está experimentando una rápida transición demográfica. El índice de envejecimiento, que refleja el tamaño de los grupos de mayor edad por 100 en comparación con los menores de 15 años, demuestra claramente el aumento de... more

Download (130)

View PDF (202)

Inclusion of Older People in Emergency Planning: Perspectives During and Beyond the COVID-19 Pandemic

World Health Organisation (WHO) (2023) C_WHO

Throughout the Americas, populations are aging and the Region is undergoing a rapid demographic transition. The aging index, which reflects the size of the older age groups per 100 compared to children under age 15, clearly demonstrates the increase in people aged 60 and older. Compared to global tr... more

External Link

Guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis: criteria and procedures

World Health Organization WHO (2016) C_WHO

Following the publication of Guidelines on certification of elimination of human onchocerciasis in 2001 by the World Health Organization (WHO), these are the first evidence-based guidelines developed by NTD Department according to the international standards. They provide a set of recommendations th... more

Download (186)

View PDF (114)

WHO Tanzania 2022 Annual Report

World Health Organisation (WHO) (2023) C_WHO

The Annual Report summarizes what has been achieved in the year 2022, how WHO supported the country priority, how WHO took the lead in health in bringing together partners to help the country achieve its strategic goals as a result be on track on its commitment on the SDG goals. The report also high... more

Download (242)

View PDF (358)

Safety and quality of water use and reuse in the production and processing of dairy products: meeting report

World Health Organisation (WHO) (2023) C_WHO

At its 48th session of Codex Committee on Food Hygiene (CCFH), the Committee noted the importance of water quality and safety in food production and processing. CCFH requested the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO) to provide guidan... more

Download (120)

View PDF (153)

Política para mejorar la salud mental

World Health Organisation (WHO) (2023) C_WHO

En este documento se presenta una política para orientar y brindar apoyo a los Estados Miembros de la Organización Panamericana de la Salud (OPS), así como a la Oficina Sanitaria Panamericana, en las actividades de cooperación técnica dirigidas a mejorar la salud mental como prioridad para fome... more

Download (135)

View PDF (158)

Morbidity management and disability prevention in lymphatic filariasis

World Health Organization (WHO) (2013) C_WHO

The content of these guidelines goes beyond the technicalities of medical needs with additional insights into community empowerment, possible access to welfare and economic opportunities and similar issues. If these are adequately explored, the health and quality of life of people affected and their... more

Download (226)

View PDF (199)

The state of food security and nutrition in the world 2023

World Health Organisation (WHO) (2023) C_WHO

This report is the annual global monitoring report documenting progress towards Sustainable Development Goal (SDG) 2 targets 2.1 and 2.2. This year’s report explores the links between urbanization and changing food systems and how these changes are impacting the availability, affordability and des... more

Download (92)

View PDF (108)

ACT-A - Urgent Priorities & Financing Requirements at 10 November 2020

World Health Organization (WHO), The Global Fund, Gavi et al. World Health Organization (WHO) (2020) CC

Six months after its launch on 24 April, the Access to COVID-19 Tools (ACT) Accelerator has already delivered concrete results in speeding up the development of new therapeutics, diagnostics, and vaccines. Now mid-way through the scale-up phase, the tools we need to fundamentally change the course o... more

Download (159)

View PDF (138)

Communicating about Vaccination-related Risks

World Health Organisation (WHO) (2023) C_WHO

This document seeks to help health communication professionals working on the topic of immunization more effectively communicate about Events Supposedly Attributed to Vaccination and Immunization (ESAVI) by building trust in National Immunization Programs, understanding risk perceptions related to v... more

Download (242)

View PDF (222)

Infection prevention and control in the context of coronavirus disease (‎COVID-19)‎: a living guideline, 9 October 2023

World Health Organization WHO (2023) CC

The Infection prevention and control in the context of coronavirus disease 2019 (COVID-19): a living guideline consolidates technical guidance developed and published during the COVID-19 pandemic into evidence-informed recommendations for infection prevention and control (IPC). This living guideline... more

Download (284)

View PDF (380)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (267)

View PDF (135)

WHO Emergency Response Framework - Internal WHO procedures - Second Edition

World Health Organization WHO (2024) C_WHO

The ERF provides WHO staff with essential guidance on how the Organization manages the assessment, grading and response to public health events and emergencies with health consequences, in support of Member States and affected communities. The ERF adopts an all-hazards approach and it is therefore a... more

Download (27)

View PDF (69)

Hearts - D: Diagnosis and Management of Type 2 Diabetes 2020

World Health Organization WHO; International Diabetes Federation (2020) C_WHO

Diabetes mellitus, commonly known as diabetes, is a group of metabolic disorders characterized by the presence of hyperglycaemia in the absence of treatment. The heterogeneous aetiopathology includes defects in insulin secretion, insulin action, or both. The long-term specific complications of diabe... more

Download (32)

View PDF (40)

Guidelines for the prevention, management and care of diabetes mellitus

World Health Organization WHO (2006) C_WHO

Diabetes mellitus is one of the most common noncommunicable diseases worldwide. In the Eastern Mediterranean Region there has been a rapid increase in the incidence of diabetes mellitus and it is now the fourth leading cause of death. The increasing prevalence of diabetes mellitus, the emergence of ... more

Download (50)

View PDF (203)

Global tuberculosis report 2024

World Health Organisation (WHO) (2024) C_WHO

The WHO Global tuberculosis report 2024 provides a comprehensive and up-to-date assessment of the TB epidemic, and of progress in prevention, diagnosis and treatment of the disease, at global, regional and country levels. This is done in the context of global TB commitments, strategies and targets.

Download (32)

View PDF (32)

SEAHEARTS Monitoring Framework

World Health Organisation (WHO) (2024) C_WHO

Monitoring Framework

Download (1308)

View PDF (1614)

Field-friendly Guide to Integrate Emergency Obstetric Care in Humanitarian Programs

Women’s Commission for Refugee Women and Children Reproductive Health Response in Conflict Consortium (2005) C1